Charles Schwab Investment Management Inc Arcellx, Inc. Transaction History
Charles Schwab Investment Management Inc
- $515 Billion
- Q3 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Arcellx, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 328,093 shares of ACLX stock, worth $24.8 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
328,093
Previous 313,893
4.52%
Holding current value
$24.8 Million
Previous $17.3 Million
58.17%
% of portfolio
0.01%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding ACLX
# of Institutions
204Shares Held
44.2MCall Options Held
2.23MPut Options Held
907K-
Paradigm Biocapital Advisors LP New York, NY4MShares$302 Million12.04% of portfolio
-
Perceptive Advisors LLC New York, NY3.89MShares$294 Million8.48% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$283 Million23.89% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$266 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.46MShares$186 Million0.0% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $3.31B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...